Parra-Herran C - Search Results

1

Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma.

Bassiouny D, Ismiil N, Dubé V, Han G, Cesari M, Lu FI, Slodkowska E, Parra-Herran C, Chiu HF, Naeim M, Li N, Khalifa M, Nofech-Mozes S. Bassiouny D, et al. Int J Surg Pathol. 2018 Jun;26(4):306-317. doi: 10.1177/1066896917752861. Epub 2018 Jan 16. Int J Surg Pathol. 2018. PMID: 29338553

2

An Assessment of Gender Equity and Parity Among "Nontraditional" Pathology Awards.

Jacobs JW, Adkins BD, Allen ES, Parra-Herran C, Stephens LD, Woo JS, Booth GS. Jacobs JW, et al. Lab Med. 2023 Sep 5;54(5):519-522. doi: 10.1093/labmed/lmac166. Lab Med. 2023. PMID: 36857473

3

Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.

Strickland S, Wasserman JK, Giassi A, Djordjevic B, Parra-Herran C. Strickland S, et al. Int J Gynecol Pathol. 2016 May;35(3):191-208. doi: 10.1097/PGP.0000000000000238. Int J Gynecol Pathol. 2016. PMID: 26535987

4

Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.

Strickland S, Parra-Herran C. Strickland S, et al. Histopathology. 2016 Jun;68(7):977-87. doi: 10.1111/his.12899. Epub 2016 Feb 2. Histopathology. 2016. PMID: 26542609

5

Morphometric Analysis in the Diagnosis of Low-Grade Ductal and Lobular Carcinoma in Situ of the Breast.

Parra-Herran C, Hope T, Rashed T, Slodkowska E, Lu FI, Nofech-Mozes S. Parra-Herran C, et al. Anal Quant Cytopathol Histpathol. 2015 Dec;37(6):331-8. Anal Quant Cytopathol Histpathol. 2015. PMID: 26860008

6

Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.

Parra-Herran C, Schoolmeester JK, Yuan L, Dal Cin P, Fletcher CD, Quade BJ, Nucci MR. Parra-Herran C, et al. Am J Surg Pathol. 2016 Mar;40(3):285-301. doi: 10.1097/PAS.0000000000000593. Am J Surg Pathol. 2016. PMID: 26866354 Review.

7

IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma.

Busca A, Djordjevic B, Giassi A, Parra-Herran C. Busca A, et al. Am J Clin Pathol. 2016 Apr;145(4):486-96. doi: 10.1093/ajcp/aqw021. Epub 2016 Mar 21. Am J Clin Pathol. 2016. PMID: 27124937 Free PMC article.

8

IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus.

Busca A, Gulavita P, Parra-Herran C, Islam S. Busca A, et al. Int J Gynecol Pathol. 2018 Jul;37(4):372-378. doi: 10.1097/PGP.0000000000000424. Int J Gynecol Pathol. 2018. PMID: 28700435

9

Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.

Hodgson A, Amemiya Y, Seth A, Cesari M, Djordjevic B, Parra-Herran C. Hodgson A, et al. Mod Pathol. 2017 Nov;30(11):1633-1641. doi: 10.1038/modpathol.2017.80. Epub 2017 Jul 21. Mod Pathol. 2017. PMID: 28731050 Free article.

10

Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Parra-Herran C, Lerner-Ellis J, Xu B, Khalouei S, Bassiouny D, Cesari M, Ismiil N, Nofech-Mozes S. Parra-Herran C, et al. Mod Pathol. 2017 Dec;30(12):1748-1759. doi: 10.1038/modpathol.2017.81. Epub 2017 Aug 4. Mod Pathol. 2017. PMID: 28776572 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters